A Sequential Bioequivalence Design with a Potential Ethical Advantage
Journal Title: The AAPS Journal - Year 2014, Vol 16, Issue 4
Abstract
The online version of this article (doi:10.1208/s12248-014-9622-7) contains supplementary material, which is available to authorized users.
Authors and Affiliations
Anders Fuglsang
Keywords
Related Articles
- EP ID EP681707
- DOI 10.1208/s12248-014-9622-7
- Views 94
- Downloads 0
k Opioids as potential treatments for stimulant dependence
Stimulant abuse is a major problem in the United States and the development of pharmacological treatments for stimulant abuse remains an important therapeutic goal. Classically, the “dopamine hypothesis”...
An Integrated Strategy for Implementation of Dried Blood Spots in Clinical Development Programs
Dried blood spot (DBS) sample collection has gained increased interest across the pharmaceutical industry as a potential alternative to plasma for pharmacokinetic (PK) evaluations. However, regulatory guidelines and exam...
Assessing the cost-effectiveness of pharmacogenomics
The use of pharmacogenomics to individualize drug therapy offers the potential to improve drug effectiveness, reduce adverse side effects, and provide cost-effective pharmaceutical care. However, the combinations of dise...
A Population Pharmacodynamic Model for Lactate Dehydrogenase and Neuron Specific Enolase to Predict Tumor Progression in Small Cell Lung Cancer Patients
The online version of this article (doi:10.1208/s12248-014-9600-0) contains supplementary material, which is available to authorized users.
Functional and Molecular Aspects of Biotin Uptake via SMVT in Human Corneal Epithelial (HCEC) and Retinal Pigment Epithelial (D407) Cells
The online version of this article (doi:10.1208/s12248-012-9399-5) contains supplementary material, which is available to authorized users.